-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, CEm6wSvnrbzLDMy0WbTkHbo6E+UYEvzlVoOVjnDzmG8igktmO/OdHDk2s5clFiLI GE8EYZ+nbhdnRH3HLrMuYA== 0001144204-06-006274.txt : 20060214 0001144204-06-006274.hdr.sgml : 20060214 20060214173057 ACCESSION NUMBER: 0001144204-06-006274 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20060214 DATE AS OF CHANGE: 20060214 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: EYETECH PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001115285 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 134104684 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-80385 FILM NUMBER: 06617667 BUSINESS ADDRESS: STREET 1: 3 TIMES SQUARE STREET 2: 12TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10036 BUSINESS PHONE: 2128243100 MAIL ADDRESS: STREET 1: 3 TIMES SQUARE STREET 2: 12TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10036 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: JP MORGAN PARTNERS BHCA LP CENTRAL INDEX KEY: 0001106607 IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: J.P. MORGAN PARTNERS STREET 2: 1221 AVENUE OF THE AMERICAS 40TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10020 BUSINESS PHONE: 2128993400 MAIL ADDRESS: STREET 1: J.P. MORGAN PARTNERS STREET 2: 1221 AVENUE OF THE AMERICAS 40TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10020 FORMER COMPANY: FORMER CONFORMED NAME: CHASE EQUITY ASSOCIATES LLC DATE OF NAME CHANGE: 20000214 SC 13G/A 1 v035452_sc13ga.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (RULE 13D-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13D-1(B)(C), AND (D) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13D-2(B) (AMENDMENT NO. 1)* Eyetech Pharmaceuticals, Inc. - -------------------------------------------------------------------------------- (Name of Issuer) Common Stock - -------------------------------------------------------------------------------- (Title of Class of Securities) 302297106 --------------------------------------------------------------------- (CUSIP Number) December 31, 2005 - -------------------------------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |_| Rule 13d-1(b) |_| Rule 13d-1(c) |X| Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). 1 of 10 SCHEDULE 13G ISSUER: Eyetech Pharmaceuticals, Inc. CUSIP NO.: 302297106 - -------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSON I.R.S. IDENTIFICATION NOS. OF ABOVE PERSON (ENTITIES ONLY). J.P. Morgan Partners (BHCA), L.P. - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) |_| (b) |_| - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware - -------------------------------------------------------------------------------- 5 SOLE VOTING POWER 0 Shares of Common Stock ----------------------------------------------------------------- NUMBER OF 6 SHARED VOTING POWER SHARES BENEFICIALLY OWNED BY ----------------------------------------------------------------- EACH 7 SOLE DISPOSITIVE POWER REPORTING PERSON 0 Shares of Common Stock WITH ----------------------------------------------------------------- 8 SHARED DISPOSITIVE POWER - -------------------------------------------------------------------------------- 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 0 Shares of Common Stock - -------------------------------------------------------------------------------- 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) |_| - -------------------------------------------------------------------------------- 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0% - -------------------------------------------------------------------------------- 12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) PN - -------------------------------------------------------------------------------- 2 of 10 SCHEDULE 13G ISSUER: Eyetech Pharmaceuticals, Inc. CUSIP NO.: 302297106 ITEM 1. (a) NAME OF ISSUER: Eyetech Pharmaceuticals, Inc. (b) ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES: 3 Times Square New York, New York 10036 ITEM 2. (a) NAME OF PERSON FILING: J.P. Morgan Partners (BHCA), L.P. Supplemental information relating to the ownership and control of the person filing this statement is included in Exhibit 2(a) attached hereto. ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE: c/o J.P. Morgan Partners, LLC 1221 Avenue of the Americas New York, New York 10020 See also supplemental information relating to principal business office is included in Exhibit 2(a) attached hereto. (b) CITIZENSHIP: Delaware (c) TITLE OF CLASS OF SECURITIES (OF ISSUER): Common Stock (d) CUSIP NUMBER: 2677606 ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SS.SS. 240. 13D-1(B) OR 240. 13D-2(B) OR (C), CHECK WHETHER THE PERSON FILING IS A: Not applicable. ITEM 4. OWNERSHIP (a) AMOUNT BENEFICIALLY OWNED: JPMP (BHCA): 0 (b) PERCENT OF CLASS: JPMP (BHCA): 0 % (as of December 31, 2005) 3 of 10 SCHEDULE 13G ISSUER: Eyetech Pharmaceuticals, Inc. CUSIP NO.: 302297106 (c) NUMBER OF SHARES AS TO WHICH SUCH PERSON HAS: (i) JPMP (BHCA): 0 (ii) Not applicable (iii) JPMP (BHCA): 0 (iv) Not applicable ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS If this statement is being filed to report the fact that as of the date hereto the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [x]. ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON Not applicable. ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON Not applicable. ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP Not applicable. ITEM 9. NOTICE OF DISSOLUTION OF GROUP Not applicable. ITEM 10. CERTIFICATION Not applicable. 4 of 10 SCHEDULE 13G ISSUER: Eyetech Pharmaceuticals, Inc. CUSIP NO.: 302297106 SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: February 14, 2006 J.P. MORGAN PARTNERS (BHCA), L.P. By: JPMP Masterfund Manager, L.P., its General Partner By: JPMP Capital Corp., its General Partner By: /s/ Jeffrey C. Walker ----------------------------------- Name: Jeffrey C. Walker Title: President 5 of 10 SCHEDULE 13G ISSUER: Eyetech Pharmaceuticals, Inc. CUSIP NO.: 302297106 EXHIBIT 2(A) Item 2. Identity and Background. This statement is being filed by J.P. Morgan Partners (BHCA), L.P., a Delaware limited partnership (hereinafter referred to as "JPMP (BHCA)"), whose principal business office is located 1221 Avenue of the Americas, New York, New York 10020. JPMP (BHCA) is engaged in the venture capital, private equity and leveraged buyout business. The general partner of JPMP (BHCA) is JPMP Master Fund Manager, L.P., a Delaware limited partnership (hereinafter referred to as "JPMP Master Fund"), whose principal business office is located at the same address as JPMP (BHCA), and is also engaged directly and indirectly (through affiliates) in the venture capital, private equity and leveraged buyout business. As general partner of JPMP (BHCA), JPMP Master Fund may be deemed to benefically own the shares held by JPMP (BHCA). The general partner of each of JPMP Master Fund is JPMP Capital Corp., a New York corporation (hereinafter referred to as "JPMP Capital Corp."), whose principal business office is located at the same address as JPMP (BHCA), and is also engaged directly and indirectly (through affiliates) in the venture capital, private equity and leveraged buyout business. Set forth in Schedule A hereto and incorporated herein by reference are the names, business addresses, principal occupations and employments of each executive officer and director of JPMP Capital Corp. As general partner of JPMP Master Fund, JPMP Capital Corp. may be deemed to beneficially own the shares held by JPMP (BHCA). JPMP Capital is a wholly owned subsidiary of JPMorgan Chase & Co., a Delaware corporation (hereinafter referred to as "JPMorgan Chase") which is engaged (primarily through subsidiaries) in the commercial banking business with its principal office located at 270 Park Avenue, New York, New York 10017. Set forth in Schedule B hereto and incorporated herein by reference are the names, business addresses, principal occupations and employments of each executive officer and director of JPMorgan Chase. 6 of 10 SCHEDULE 13G ISSUER: Eyetech Pharmaceuticals, Inc. CUSIP NO.: 302297106 SCHEDULE A JPMP CAPITAL CORP. EXECUTIVE OFFICERS(1) Chief Executive Officer William B. Harrison** President Jeffrey C. Walker* Chief Investment Officer Arnold L. Chavkin* Managing Director Srinivas Akkaraju* Managing Director Christopher Albinson* Managing Director Dr. Dana Beth Ardi* Managing Director Christopher C. Behrens* Managing Director John Breckenridge* Managing Director Julie Casella-Esposito* Managing Director Rodney A. Ferguson* Managing Director Michael R. Hannon* Managing Director Matthew Lori* Managing Director Jonathan R. Lynch* Managing Director Sunil Mishra* Managing Director Stephen P. Murray* Managing Director John Reardon* Managing Director Faith Rosenfeld* Managing Director Shahan D. Soghikian* Managing Director William Stuek* Managing Director Timothy J. Walsh* Managing Director Richard D. Waters, Jr. * Managing Director Damion E. Wicker, M.D.* DIRECTORS(1) William B. Harrison** Jeffrey C. Walker* - ---------- (1) Each of whom is a United States citizen. * Principal occupation is employee and/or officer of J.P. Morgan Partners, LLC. Business address is c/o J.P. Morgan Partners, LLC, 1221 Avenue of the Americas, New York, New York 10020. ** Principal occupation is employee or officer of J.P. Morgan Chase & Co. Business address is c/o J.P. Morgan Chase & Co., 270 Park Avenue, New York, New York 10017. (1) Each of whom is a United States citizen * Principal occupation is employee or officer of JPMorgan Chase & Co. Business address is c/o JPMorgan Chase & Co., 270 Park Avenue, New York, New York 10017. 7 of 10 SCHEDULE 13G ISSUER: Eyetech Pharmaceuticals, Inc. CUSIP NO.: 302297106 SCHEDULE B JPMORGAN CHASE & CO.
EXECUTIVE OFFICER(1) Chairman of the Board William B. Harrison Jr.* President and Chief Executive Officer James Dimon* Chief Information Officer Austin A. Adams* Co-CEO, Investment Bank Steven D. Black* Chief Executive Officer and Executive Vice President, Card Services Richard J. Srednicki* Chief Financial Officer Michael J. Cavanagh* Chief Administrative Officer Frank Bisignano * Director of Human Resources John F. Bradley* Co-General Counsel Joan Guggenheimer* Chief Investment Officer Ina R. Drew * Head, Commercial Banking Samuel Todd Maclin* Head, Strategy Jay Mandelbaum* Co-General Counsel William H. McDavid* Treasury & Securities Services Heidi Miller* Head, Retail Financial Services Charles W. Scharf* Head, Asset & Wealth Management James E. Staley* Chief Risk Officer Don M. Wilson III* MD & Co-CEO, Investment Bank William T. Winters*
- ---------- (1) Each of whom is a United States citizen. * Principal occupation is employee or officer of JPMorgan Chase & Co. Business address is c/o JPMorgan Chase & Co., 270 Park Avenue, New York, New York 10017. 8 of 10 SCHEDULE 13G ISSUER: Eyetech Pharmaceuticals, Inc. CUSIP NO.: 302297106
DIRECTORS(1) NAME PRINCIPAL OCCUPATION OR EMPLOYMENT; BUSINESS OR RESIDENCE ADDRESS - -------------------------------------------------------------------------------------------------- Hans W. Becherer Retired Chairman of the Board and Chief Executive Officer Deere & Company c/o JPMorgan Chase & Co. 270 Park Avenue New York, New York 10017 - -------------------------------------------------------------------------------------------------- John H. Biggs Former Chairman and CEO TIAA - CREF c/o JPMorgan Chase & Co. 270 Park Avenue New York, New York 10017 - -------------------------------------------------------------------------------------------------- Lawrence A. Bossidy Retired Chairman of the Board Honeywell International Inc. c/o JPMorgan Chase & Co. 270 Park Avenue New York, New York 10017 - -------------------------------------------------------------------------------------------------- Stephen B. Burke President Comcast Cable Communications, Inc. c/o JPMorgan Chase & Co. 270 Park Avenue New York, New York 10017 - -------------------------------------------------------------------------------------------------- James S. Crown President Henry Crown and Company c/o JPMorgan Chase & Co. 270 Park Avenue New York, New York 10017 - -------------------------------------------------------------------------------------------------- James Dimon President and Chief Executive Officer JPMorgan Chase & Co. 270 Park Avenue, 8th Floor New York, New York 10017-2070 - -------------------------------------------------------------------------------------------------- Ellen V. Futter President and Trustee American Museum of Natural History c/o JPMorgan Chase & Co. 270 Park Avenue New York, New York 10017 - -------------------------------------------------------------------------------------------------- William H. Gray, III Retired President and Chief Executive Officer The College Fund/UNCF c/o JPMorgan Chase & Co. 270 Park Avenue New York, New York 10017 - -------------------------------------------------------------------------------------------------- - ---------- (1) Each of whom is a United States citizen. 9 of 10 SCHEDULE 13G ISSUER: Eyetech Pharmaceuticals, Inc. CUSIP NO.: 302297106 - -------------------------------------------------------------------------------------------------- William B. Harrison, Jr. Chairman of the Board JPMorgan Chase & Co. 270 Park Avenue, 8th Floor New York, New York 10017-2070 - -------------------------------------------------------------------------------------------------- Laban P. Jackson, Jr. Chairman and Chief Executive Officer Clear Creek Properties, Inc. c/o JPMorgan Chase & Co. 270 Park Avenue New York, New York 10017 - -------------------------------------------------------------------------------------------------- Lee R. Raymond Chairman of the Board and Chief Executive Officer Exxon Mobil Corporation c/o JPMorgan Chase & Co. 270 Park Avenue New York, New York 10017 - -------------------------------------------------------------------------------------------------- John W. Kessler Owner John W. Kessler Company c/o JPMorgan Chase & Co. 270 Park Avenue New York, New York 10017 - -------------------------------------------------------------------------------------------------- Robert I. Lipp Senior Advisor JPMorgan Chase & Co. 270 Park Avenue New York, New York 10017 - -------------------------------------------------------------------------------------------------- Richard A. Monoogian Chairman and Chief Executive Officer Masco Corporation c/o JPMorgan Chase & Co. 270 Park Avenue New York, New York 10017 - -------------------------------------------------------------------------------------------------- David C. Novak Chairman and Chief Executive Officer Yum! Brands, Inc. c/o JPMorgan Chase & Co. 270 Park Avenue New York, New York 10017 - -------------------------------------------------------------------------------------------------- William C. Weldon Chairman and Chief Executive Officer Johnson & Johnson c/o JPMorgan Chase & Co. 270 Park Avenue New York, New York 10017 - --------------------------------------------------------------------------------------------------
10 of 10 -----END PRIVACY-ENHANCED MESSAGE-----